A worried mum. A daughter needing insulin. A train station bathroom. One moment that sparked 40 years of life-changing innovation and changed diabetes care forever. Learn how we turn real human challenges into breakthrough solutions 💡 https://lnkd.in/dKrxT3PH #UnordinaryDrivesChange
Novo Nordisk
Produktion af lægemidler
We’re here to champion long-term health. Get updates on innovation and inspiring stories 💙 #UnordinaryDrivesChange
Om os
We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html
- Websted
-
https://www.novonordisk.com
Eksternt link til Novo Nordisk
- Branche
- Produktion af lægemidler
- Virksomhedsstørrelse
- Over 10.001 medarbejdere
- Hovedkvarter
- Bagsværd
- Type
- Aktieselskab
- Grundlagt
- 1923
- Specialer
- Pharmaceuticals, Insulin, obesity, Rare Diseases og Diabetes
Beliggenheder
Medarbejdere hos Novo Nordisk
-
Karen J. Kolin
Clinical Research Relationship Specialist
-
Thomas Røygaard
PMO | Digital Transformation | Leading Program, Project and Portfolio Management | Governance | Change Management
-
Sören Meelby
Digital Healthcare Evangelist | Cultivating Partnerships for Collective Impact & Social Good
-
Henrik Vestergaard
Opdateringer
-
Is weight loss predominantly about appearance? Think again. For people living with obesity, losing just 5–10% of body weight can lead to major health wins, like better heart health, a lower risk of type 2 diabetes, and even reversing early liver disease (MASH). We’re on a mission to drive long-term health, and would like to hear from you 👇 #UnordinaryDrivesChange
Dette indhold er ikke tilgængeligt her
Få adgang til dette indhold og meget mere i LinkedIn-appen
-
For people with obesity, weight loss may help change appearances but do you know about the long-term benefits? Our colleague Rochelle is here to set the record straight. From reducing the risk of type 2 diabetes by 58% to even reversing liver disease. Learn about the science of obesity: https://lnkd.in/eCyWpsQ #UnordinaryDrivesChange
-
40 years ago, we wrote a new chapter in insulin delivery by introducing the first reusable injection pen to patients. Since then, we’ve continued to innovate to support healthier lives for people living with serious chronic diseases – and today, injection pens are used for treatments beyond diabetes. #UnordinaryDrivesChange
Dette indhold er ikke tilgængeligt her
Få adgang til dette indhold og meget mere i LinkedIn-appen
-
This is great for everyone living with type 1 diabetes and their friends! 💙
Barbie and Breakthrough T1D are proud to partner on the first-ever Barbie doll with type 1 diabetes, designed with inclusion and empathy at the core. 💙 To ensure the doll design truly captures the community, Barbie partnered with Breakthrough T1D , the leading global type 1 diabetes research and advocacy organization committed to accelerating life-changing breakthroughs to cure, prevent, and treat type 1 diabetes and its complications. Barbie also honored two global role models and type 1 diabetes advocates – Peloton Instructor Robin Arzón in the US and model Lila Moss in the UK – with their own one-of-a-kind Barbie dolls. Find out more here: https://lnkd.in/gVY5iTjp
-
-
Why did our founders choose the Apis bull as our logo over a hundred years ago? The story behind our logo and who we are might surprise you… Learn more here: https://lnkd.in/d_86Rh5T #UnordinaryDrivesChange
-
As June comes to a close, we proudly reflect on a month filled with a variety of activities celebrating diversity, inclusion, and driving equal opportunities for a healthy life for everyone. Our colleagues from across the world came together to participate in meaningful activities, including: 🌈 Flag raising ceremonies 🏃♂️ Pride walks and sports events 💬 Engaging dialogues We believe in driving everyday inclusion, not just during Pride Month, but all year round. Together, we can create environments where everyone feels valued and empowered to live their healthiest lives. Swipe through to see highlights from our activities and share your photos in the comments. #PrideMonth
-
-
-
-
-
+ 2
-
-
In times of growth, reducing our environmental footprint is no easy task - but we continue to find solutions that help us speed up and deliver on our commitment. Using biobased ammonia in the fermentation processes that create our medicines is a recent example of how we are switching to low-carbon solutions to cut our C02 emissions. Thanks to Corporate Knights for ranking us as one of the 50 Most Sustainable Corporations in Europe - 2025. Rankings like these help set global sustainability standards while holding us accountable. Curious to learn more about our actions? Read more here https://lnkd.in/d2QGjEdg
-
Did you know that almost 8 million people globally live with sickle cell disease, with the majority of cases concentrated in Sub-Saharan Africa? The need for change is urgent. This #WorldSickleCellDay, we're proud to take action, alongside American Society of Hematology and reach52, by empowering health workers, advancing newborn screening, and fostering awareness campaigns to address stigma and promote better health-seeking behaviours in underserved communities. Together, we can improve outcomes for those affected. Vote below or share your 💬 in the comments 👇
Dette indhold er ikke tilgængeligt her
Få adgang til dette indhold og meget mere i LinkedIn-appen
-
“One of the reasons that drove me to initiate this running club is to foster an environment of inclusion.” When Matthew moved from Australia to Denmark, he discovered Pan Idræt's running club as a great way to connect with like-minded people. He decided to start a running club at one of our Copenhagen sites in Denmark, where colleagues within the LGBTQ+ community and beyond can come together to meet, run and connect. “I think it’s extremely important in the workplace that we all feel included - because we do truly work at our best when we’re in that sort of environment,” says Matthew. Read more about our commitment to support the LGBTQ+ community here: https://lnkd.in/dfT5m4AS #DrivingChange #Pride
-
Tilsvarende sider
Finansiering
Seneste runde
Post IPO-egenkapital22.000.000,00 US$